GSK•benzinga•
GSK Highlights New Approvals, Vaccine Momentum At JPMorgan Healthcare Conference
Summary
GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 15, 2025 by benzinga